Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gland PharmaNSE:GLAND -0.93%84 Return-on-Tangible-Asset is 12.11% as of Mar. 2026, which is 10% above its 10-year median of 10.96. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,140.91 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Gland Pharma ranks better than 74.93% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Gland Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹14,667 Mil. Gland Pharma's average total tangible assets for the quarter that ended in Mar. 2026 was ₹121,084 Mil. Therefore, Gland Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 12.11%.
The historical rank and industry rank for Gland Pharma's Return-on-Tangible-Asset or its related term are showing as below:
NSE:GLAND'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.6 Med: 10.96 Max: 20.31
Current: 8.96
During the past 9 years, Gland Pharma's highest Return-on-Tangible-Asset was 20.31%. The lowest was 6.60%. And the median was 10.96%.
NSE:GLAND's Return-on-Tangible-Asset is ranked better than 74.93% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs NSE:GLAND: 8.96
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Gland Pharma Return-on-Tangible-Asset Related Terms
Gland Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAND vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.11% mean?
Gland Pharma (NSE:GLAND) has a Return-on-Tangible-Asset of 12.11% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gland Pharma and its competitors. This is 10% above median its historical median of 10.96. Over the past decade, Gland Pharma's Return-on-Tangible-Asset has ranged from 6.60 to 20.31. According to the industry distribution chart, Gland Pharma ranks #253 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 25.1%.
Is Gland Pharma's Return-on-Tangible-Asset too high?
Gland Pharma's current Return-on-Tangible-Asset of 12.11% is 10% above median its 10-year median of 10.96. Over the past 10 years, this metric has ranged from a low of 6.60 to a high of 20.31. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Gland Pharma's value of 12.11% is 283.2% above this industry median. Based on the distribution chart, Gland Pharma ranks #253 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #253 out of 1009 companies for Return-on-Tangible-Asset. This puts Gland Pharma in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Gland Pharma's value of 12.11% is 283.2% above this benchmark. Historically, Gland Pharma's own Return-on-Tangible-Asset has ranged from 6.60 to 20.31 over the past decade. While the company's 10-year median is 10.96 vs. the industry median of 3.16, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current Return-on-Tangible-Asset of 12.11% is 283.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Return-on-Tangible-Asset is 12.11%, which is 10% above median its own 10-year median of 10.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,140.91, compared to a current price of ₹2,465.10 — trading 15.1% above its estimated fair value. The current Return-on-Tangible-Asset is 12.11%, which is 10% above median its 10-year median of 10.96 and 283.2% above the Drug Manufacturers industry median of 3.16. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Return-on-Tangible-Asset is 12.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,465.10 is trading 15.1% above its estimated GF Value™ of ₹2,140.91.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
Return-on-Tangible-Asset: 12.11% (10% above median its 10-year median of 10.96)
GF Value™: ₹2,140.91 vs. price of ₹2,465.10 (15.1% above fair value)
Industry Position: 283.2% above the Drug Manufacturers median (#253 of 1009)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for NSE:GLAND
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
